Myelodysplastic syndrome with excess blasts-1

Summary

Myelodysplastic syndrome with excess blasts-1 (MONDO:0015040) is a disease and 8 clinical trials. Top therapeutic interventions include cyclosporine, vorinostat, and hu8f4. A subtype of myelodysplastic syndrome with excess blasts — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	myelodysplastic syndrome with excess blasts-1
Mondo ID	MONDO:0015040
Orphanet	100019
NCIT	C7167
UMLS	C1318550
MedGen	231145
GARD	0019737
Is cancer (heuristic)	no

Also known as: MDS-EB-1 · myelodysplastic syndrome with Excess blasts-1 · RAEB-1 · RAEB-I · refractory anaemia with excess blasts type 1

Disease family

This is a subtype of myelodysplastic syndrome with excess blasts. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › myeloid hemopathy › myelodysplastic syndrome › myelodysplastic syndrome with excess blasts › myelodysplastic syndrome with excess blasts-1

Related subtypes (1): myelodysplastic syndrome with excess blasts-2

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	6
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04636918	PHASE4	UNKNOWN	Ikervis for DED Due to GVHD Post Allo-HSCT
NCT01522976	PHASE2	ACTIVE_NOT_RECRUITING	Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT03779854	PHASE2	RECRUITING	Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT05805605	PHASE2	RECRUITING	Allo HSCT Using RIC and PTCy for Hematological Diseases
NCT01858740	PHASE2	COMPLETED	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
NCT02220985	PHASE2	COMPLETED	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
NCT06247917	PHASE2	UNKNOWN	Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS
NCT02530034	PHASE1	ACTIVE_NOT_RECRUITING	Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOSPORINE	4	1
VORINOSTAT	4	1
HU8F4	1	1
CHEMBL406352	0	1